We are the Liam's parents and we would like to clarify, that although it may seem cruel, we understand and respect the position of the pharmaceutical to strictly follow the eligibility criteria of their study. Our sadness is that Isis refuses to grant the three experimental doses despite a special authorization granted by Health Canada, the equivalent of compassion access the FDA in the United States. The authorization provided by the Special Access Programme to drug released from all responsibilities this pharmaceutical. Isis could collect additional data without creating noise in the current study. We follow the developpement of this compound and be confident its the good for our child. In addition, if you know this disease (SMA TYPE1) you know that now is the time or never to help.